Evidence map›Paper›PMID 29088292›Full record

ArticlePloS one2017

Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.

Mette Ølgod Pedersen, Anne Ortved Gang, Peter Brown, Michael Pedersen, Helle Knudsen, Signe Ledou Nielsen, Tim Poulsen, Tobias Wirenfeldt Klausen, Estrid Høgdall, Peter Nørgaard

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mette Ølgod PedersenDept. of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark.ORCID http://orcid.org/0000-0002-8561-9421
Anne Ortved GangDept. of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark.
Peter BrownDept. of Hematology, Rigshospitalet, Copenhagen, Denmark.
Michael PedersenDept. of Hematology, Rigshospitalet, Copenhagen, Denmark.
Helle KnudsenDept. of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark.
Signe Ledou NielsenDept. of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark.
Tim PoulsenDept. of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark.
Tobias Wirenfeldt KlausenDept. of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark.
Estrid HøgdallDept. of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark.
Peter NørgaardDept. of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark.
Gentofte Hospital · DKRigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDouble expression of MYC and BCL2 proteins (DE) and double-hit MYC+BCL2/BCL6 translocations (DH) were established as important biomarkers in patients with diffuse large B-cell lymphoma (DLBCL) by the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Whether this applies to the subgroup of young patients with high risk DLBCL is not known. We previously found that in a uniform retrospective population-based cohort of patients aged 18-60 years with high-risk DLBCL, the addition of etoposide to R-CHOP chemotherapy (R-CHOEP) resulted in improved survival mainly in patients with germinal center B-cell like (GCB) immunophenotype. The aim of this study was to investigate the prognostic and predictive value of DE and DH in this patient cohort.

methodsData on all young Danish patients diagnosed with de novo high-risk DLBCL 2004-2008 and treated with R-CHOP or R-CHOEP were obtained from the Danish Lymphoma database (n = 159). Tumor samples were available from 103 patients. MYC and BCL2 proteins were analyzed with quantitative immunohistochemistry (IHC) using different cut off values. MYC-, BCL2- and BCL6-translocations were examined with fluorescent in situ hybridization (FISH).

resultsDE with MYC>75% and BCL2>85% was an independent negative prognostic marker of progression free survival (PFS) in patients treated with R-CHOP but not R-CHOEP (p<0.001), also after exclusion of patients with DH. A predictive effect of DE for response (PFS) to R-CHOEP vs. R-CHOP was almost significant (p = 0.07). DH was not prognostic in this patient cohort.

conclusionIn young patients with high-risk DLBCL, treatment with R-CHOEP may overcome the negative prognostic impact of DE observed in patients treated with R-CHOP.

Indexed as

AdolescentAdultAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCyclophosphamideDoxorubicinEtoposideFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedAntibodies, Monoclonal, Murine-DerivedBCL6 protein, humanBiomarkers, TumorCyclophosphamideDoxorubicinEtoposideMYC protein, humanPrednisoneProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycVincristine

Identifiers

PMID29088292
PMCPMC5663399
OpenAlexW2765685049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.